Introduction {#sec1_1}
============

Lung cancer is a common malignancy which is frequently found to metastasize to distant sites. The most common location of these metastases are to bone, liver, and adrenal glands. There are reports of metastases to the gastrointestinal (GI) tract; however, it is uncommon \[[@B1], [@B2]\]. When lung cancer does metastasize to the GI tract, it is usually found in the jejunum, followed by the ileum, with the duodenum being a rare location \[[@B1]\]. In addition to endoscopic examination, immunohistochemical (IHC) staining and histological analysis are key to the diagnosis, as it is often necessary to differentiate between different carcinomas or to distinguish a primary tumor from a metastatic tumor. We present the case of a 61-year-old male with a history of poorly differentiated lung carcinoma, who was found to have a duodenal mass on esophagogastroduodenoscopy (EGD) diagnosed as metastatic poorly differentiated lung carcinoma after histological analysis.

Case Presentation {#sec1_2}
=================

A 61-year-old male with a past medical history of chronic obstructive pulmonary disease, lung cancer, and peptic ulcer disease presented with 1 month of worsening dizziness, fatigue, and early satiety. He stated that his dizziness occurred more with changes in position and he was having increasing limitations with his routine activities such as cooking and performing small house chores. He reported decreased exercise tolerance as he noticed he had shortness of breath after walking 1--2 blocks, which decreased from his baseline of above 5 blocks. He also reported palpitations but denied leg swelling, worsening cough, or orthopnea. During this time period, he also reported nausea, decreased appetite, and nonspecific, dull, non-radiating abdominal pain, especially after eating. He denied any hematochezia but admitted to occasional dark-colored stools. He denied any diarrhea, constipation, or use of pain medications, including over-the-counter nonsteroidal anti-inflammatory drugs. He was using a proton pump inhibitor, but stated it provided little relief. He denied any family history of malignancies but admitted to a 20-pack year history of smoking.

On admission, the patient was afebrile, tachycardic with a heart rate of 115, and had a blood pressure of 92/60. His examination was notable for skin pallor, dry mucous membranes, and a cachectic appearance. Labs were significant for a hemoglobin (Hb) of 7.2 g/dL (baseline being around 12--13), a mildly elevated blood urea nitrogen of 27 mg/dL, albumin of 3.1 g/dL, and normal prothrombin time, partial thromboplastin time, international normalized ratio, bilirubin, and lactate.

Of note, the patient was recently diagnosed with lung cancer 6 months prior to his presentation. At that time, he was complaining of chronic hemoptysis, unintentional 15-pound weight loss, and worsening fatigue over a 6-month time period. Prior chest X-rays were negative; however, a computerized tomography (CT) scan of the chest showed a new left-sided lobulated, apical lesion measuring 4 × 2 cm with bronchial involvement, and hilar lymphadenopathy (Fig. [1](#F1){ref-type="fig"}). The patient was worked up for an infectious source, including tuberculosis, which ended up being negative. He had a bronchoscopy with bronchoalveolar lavage and a transbronchial biopsy done, which showed inflammatory cells but was negative for any malignant cells on brushing or washing. However, due to a high suspicion for malignancy, the patient ultimately had a transthoracic fine-needle aspiration (FNA) of the mass. The final pathology results demonstrated poorly differentiated carcinoma that was weakly positive (only a few scattered cells) for CK-7, synaptophysin, and calretinin on IHC staining (Fig. [2](#F2){ref-type="fig"}). IHC staining of the specimen was also negative for CK-20, p63, TTF-1, chromogranin, melan-A, CDX-2, PSA, and PSMA (Fig. [2](#F2){ref-type="fig"}). The patient was further worked up for his malignancy with a magnetic resonance imaging scan of the brain which was negative for any lesions. However, a positron emission tomography scan was done and found an active left upper-lobe apical mass as well as hypermetabolic mediastinal and hilar lymphadenopathy, which were compatible with metastatic disease. His pretreatment stage at the time was determined to be T4N2M0, stage IIIB. He was started on a paclitaxel/carboplatin chemotherapy regimen with concurrent radiation therapy (total of 6,000 cgy) and was in the process of planning a surgical resection evaluation of the lung tumor prior to his hospitalization.

The patient was stabilized with fluid resuscitation and received 2 initial units of packed red blood cells. An EGD was done and showed an ulcer in the third portion of the duodenum with heaped-up borders and evidence of oozing (Fig. [3](#F3){ref-type="fig"}). Bipolar cautery was performed, and biopsies were obtained which showed poorly differentiated carcinoma histologically (Fig. [2](#F2){ref-type="fig"}). IHC staining of the duodenal mass was negative for CK-20, p63, P-40, Napsin-A, CDX-2, TTF-1, chromogranin, calretinin, CD-20, CD-3, SOX-10, and melan-A (Fig. [2](#F2){ref-type="fig"}). The patient\'s Hb continued to drop post cauterization, and he required multiple additional transfusions. He was deemed a poor surgical candidate due to his comorbidities and metastatic disease and eventually had a palliative gastroduodenal artery embolization. After embolization, the patient\'s Hb stabilized, and he was ultimately discharged after monitoring his hemodynamics, with close outpatient follow-up for further care as he wanted to continue to pursue medical therapies.

Discussion {#sec1_3}
==========

Lung cancer most often metastasizes to the bones, liver, and adrenal glands; metastasis to the GI system is rare with studies showing a frequency of only 0.2--1.7% \[[@B1], [@B2]\]. Other autopsy studies demonstrated a slightly higher prevalence of 4.7--14% \[[@B3], [@B4]\]. In support of the rarity, a report by Oda et al. \[[@B5]\] on the primary foci of gastric metastases from various cancers found lung cancer to be 6.8% (84/1,235 cases), breast cancer 11.6% (61/526 cases), esophageal cancer 11.5% (49/427 cases), and malignant melanoma 29.6% (21/71 cases). Lung cancer metastases to the GI tract are primarily found in advanced disease stages. In 64 documented cases, the most common site of primary lung metastasis to the GI tract was the jejunum (50.9%), followed by the ileum (33.3%), with the duodenum being relatively uncommon (15.8%) \[[@B1]\]. Although any tumor cell types of lung cancer can develop GI metastases, the most common type to metastasize is squamous cell, followed by large cell, and then adenocarcinoma \[[@B6]\].

The symptoms of metastasis to the GI tract are nonspecific, making early diagnosis difficult. Generally, the most common symptoms of metastasis to the GI tract are abdominal pain, cramping, nausea, vomiting, weight loss, and constipation \[[@B7], [@B8], [@B9]\]. Moreover, complications of these metastases often include GI perforation, obstruction, and hemorrhage, whereas complications such as pneumoperitoneum and intussusception are relatively uncommon \[[@B5], [@B10]\]. Total-body imaging used during lung cancer staging may increase the discovery of GI masses \[[@B11]\]. However, adding to the diagnostic challenge, imaging studies, such as a CT scan of the abdomen, generally have a low sensitivity for detecting GI metastases \[[@B12]\]. When discovered on CT imaging, GI metastases have been visualized as either wall thickening, an exophytic mass, or an intraluminal polypoid mass \[[@B13]\].

IHC staining and histological analysis are crucial for cancer diagnosis as it is often necessary to differentiate between different carcinomas or to distinguish a primary tumor from a metastatic tumor. In general, adenocarcinoma can be diagnosed with morphological findings of acinar/tubular structures or mucin production as well as IHC-positive markers for TTF-1 and/or Napsin-A. Squamous cell carcinoma (SCC) is usually defined by keratinization or intercellular bridges with associated IHC markers such as P-40, P-63, and CK-5/CK-6, with P-40 being the most sensitive and specific \[[@B14]\]. Neuroendocrine tumors are usually categorized into 3 subtypes: small cell lung carcinoma, large cell neuroendocrine carcinoma, and carcinoid tumor. All subtypes share features of neuroendocrine differentiation with IHC expression of at least one neuroendocrine marker including chromogranin A, synaptophysin, or CD-56 \[[@B14]\]. Moreover, levels of CK-7, CK-20, and TTF-1 have been used to distinguish pulmonary and GI carcinomas \[[@B15]\]. Lung adenocarcinomas often have the TTF-1 (+)/CK-7 (+)/CK-20 (−) immunoprofile, whereas GI adenocarcinomas usually have the TTF-1 (−)/CK-7 (−)/CK-20 (+) profile \[[@B16]\]. In one study, CK-7 and TTF-1 were found to be co-expressed in lung adenocarcinomas, even those that were poorly differentiated \[[@B2]\]. To help differentiate between primary lung and GI tumors, IHC staining for CDX-2 is often utilized as it is frequently expressed in primary intestinal adenocarcinomas; thus, negative staining of an intestinal lesion for CDX-2 with positive CK-20 staining often indicates a metastasis from a non-GI tumor \[[@B2]\].

Literature review, to the best of our knowledge, focusing specifically on duodenal metastasis of lung cancer, demonstrated only 16 cases. Based on those case reports, 7 cases (44%) were adenocarcinoma, 5 cases (31%) SCC, and 2 (12.5%) cases of both large and small cell carcinoma (Table [1](#T1){ref-type="table"}). For the present case, the pathology results of the FNA showed sheets of atypical cells with focal necrosis, and prominent nucleoli being dispersed without a specific pattern, consistent with a diagnosis of poorly differentiated carcinoma with focal neuroendocrine differentiation (Fig. [2](#F2){ref-type="fig"}). IHC staining of the lung mass was negative for CK-20, p63, TTF-1, chromogranin, and melan-A which was immunohistochemically identical to the duodenal mass biopsy, which also showed poorly differentiated carcinoma histologically (Fig. [2](#F2){ref-type="fig"}). The IHC profile of both biopsies could not pinpoint a specific type of carcinoma, and histological analysis only showed areas of focal neuroendocrine differentiation; highlighting the unique aspect of this case.

The exact mechanism of GI metastasis from a primary lung cancer is still being established; yet, it has been hypothesized that it occurs through hematogenous spread via the spiral veins or lymphogenous spread from the mediastinum to the retroperitoneum and mesentery. Other theories revolve around direct invasion of tumor cells or intraperitoneal dissemination \[[@B17], [@B18]\]. Moreover, several hypotheses on the origin of SCC in the duodenum have been suggested, including isolated ectopic squamous cells, transformation of basal cells into squamous cells, chronic mucosal insults leading to squamous metaplasia, and multipotent stem cells in the GI mucosa \[[@B10], [@B17], [@B18], [@B19]\].

In cases of high clinical suspicion, especially in uninvestigated anemia or melena, endoscopic evaluation and biopsy is highly recommended. On endoscopy, most metastatic lesions present as "volcano-like tumors" or submucosal tumors with bridging folds and superficial ulcerations \[[@B20], [@B21]\]. Moreover, capsule endoscopy has been shown to be more effective in detecting small bowel abnormalities when compared to push enteroscopy and is usually indicated for cases of obscure GI bleeds \[[@B22]\]. The literature also has evidence of technetium-labelled red blood cell scans being used to successfully locate the source of bleeding from a primary lung cancer metastasis to the small bowel \[[@B10]\]. In this case, the patient presented with nonspecific symptoms including early satiety, vague abdominal pain, and melena. However, more specifically, he was noted to have a significant drop in his Hb levels compared to his baseline, with signs of hemodynamic abnormalities which prompted an urgent EGD. His EGD showed an ulcerative mass in the third portion of the duodenum with heaped-up borders and evidence of bleeding.

The treatment of duodenal metastasis tends to be challenging, and it depends on variables including the site of the duodenal involvement, patient characteristics, and size of the lesions. Endoscopic resection of smaller duodenal metastatic lesions (≤1 cm) has been shown to be safe and effective, especially in cases where complete resection is obtainable solely by endoscopic methods \[[@B23]\]. Surgical treatment of duodenal metastases has not been shown to increase survival but is often pursued for palliative relief \[[@B24], [@B25]\]. Surgical treatment often consists of a duodenectomy or pancreaticoduodenectomy (Whipple procedure) \[[@B26]\]. Unfortunately, GI metastasis from lung cancer usually indicates a very poor prognosis \[[@B24], [@B25]\]. The mean survival time after discovery of GI metastasis ranges from 2 to 4 months according to Morris and Deitsch \[[@B27]\] and Wiedemer \[[@B28]\], respectively. In this case, surgical treatment was not recommended due to the patient\'s comorbidities and metastatic disease; a palliative gastroduodenal artery embolization was ultimately performed with good response.
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![A CT scan of the chest from the patient\'s prior hospitalization (top image) showing a large, lobulated, left apical lung mass (arrow). Transthoracic FNA results later came back positive for poorly differentiated lung carcinoma with focal neuroendocrine differentiation. The bottom image is from a CT scan of the abdomen that was done on presentation, which shows a large elliptical lesion (arrow) around the third portion of the duodenum, later found on esophagogastroduodenoscopy, whose biopsies were consistent with metastatic lung carcinoma.](crg-0014-0186-g01){#F1}

![**a**, **b** H&E stain under ×20 magnification demonstrating a poorly differentiated malignant neoplasm with focal neuroendocrine differentiation in the lung biopsy. **c**, **d** H&E stain under ×20 magnification demonstrating a poorly differentiated neoplasm in the duodenal mass biopsy. **e--h** IHC stains (×20) from the lung. **e** Negative CK-20 stain. **f** Negative P-63 stain. **g** Negative TTF-1 stain. **h** Negative chromogranin stain. **i--l** IHC stains from the duodenum (×20). Identical to the lung samples, **i** shows a negative CK-20 stain, and **j** shows a negative TTF-1 stain. **k** Negative CDX-2 stain of the duodenal biopsy. Weakly positive lung biopsy stains (×20) demonstrating CK-7 (**l**), synaptophysin (**m**), and calretinin (**n**). IHC staining of both biopsies were similar; however, ultimately the diagnosis was of undifferentiated histogenesis.](crg-0014-0186-g02){#F2}

![Endoscopic images done during the patient\'s hospital course. The images demonstrate a large, oozing, edematous, heaped-up lesion with an ulcerated center in the third portion of the duodenum. The bottom right image was taken after an endoscopic bipolar electrocautery procedure. Biopsies from the lesion demonstrated metastatic disease histologically similar to his primary lung cancer.](crg-0014-0186-g03){#F3}

###### 

Previously published case reports of duodenal metastasis from a primary lung carcinoma

  Age, years/sex   Symptoms                                                                Time of diagnosis                                         Location                                                   Histopathology            Treatment                                                               Reference
  ---------------- ----------------------------------------------------------------------- --------------------------------------------------------- ---------------------------------------------------------- ------------------------- ----------------------------------------------------------------------- -----------
  63/M             Melena, microcytic anemia                                               24 months after treatment for primary lung cancer         3rd part of duodenum                                       Squamous cell arcinoma    Duodenectomy                                                            23
                                                                                                                                                                                                                                                                                                                  
  66/M             Perforation                                                             During chemoradiation for primary lung cancer             4th part of duodenum                                       Squamous cell carcinoma   Duodenectomy, followed by chemotherapy                                  18
                                                                                                                                                                                                                                                                                                                  
  75/M             Melena, microcytic anemia, intussusception                              At time of diagnosis for primary lung cancer              2nd and 3rd parts of duodenum                              Small cell carcinoma      Pancreaticoduoden-ectomy                                                38
                                                                                                                                                                                                                                                                                                                  
  58/M             Obstruction                                                             2 years after treatment for primary lung cancer           2nd part of duodenum                                       Large cell carcinoma      Pancreaticoduoden-ectomy followed by chemotherapy                       29
                                                                                                                                                                                                                                                                                                                  
  46/F             Melena, microcytic anemia                                               20 days after treatment for primary lung cancer           4th part of duodenum                                       Large cell carcinoma      Duodenectomy, followed by chemotherapy                                  30
                                                                                                                                                                                                                                                                                                                  
  61/M             Melena, weight loss, hemoptysis                                         At time of diagnosis for primary lung cancer              4th part of duodenum                                       Adenocarcinoma            Endoscopic resection, chemotherapy, blood transfusion, erythropoietin   31
                                                                                                                                                                                                                                                                                                                  
  55/M             Upper GI bleeding                                                       Unknown                                                   3rd part of duodenum invading superior mesenteric artery   Adenocarcinoma            Not specified                                                           32
                                                                                                                                                                                                                                                                                                                  
  66/M             Upper GI bleeding                                                       8 months after treatment for primary lung cancer          Not specified                                              Adenocarcinoma            Not specified                                                           33
                                                                                                                                                                                                                                                                                                                  
  65/M             Jaundice, obstruction                                                   Unknown                                                   2nd part of duodenum                                       Squamous cell carcinoma   Endoscopic resection                                                    34
                                                                                                                                                                                                                                                                                                                  
  54/M             Dysphagia                                                               During chemoradiation for primary lung cancer             1st and 2nd parts of duodenum                              Squamous cell carcinoma   Endoscopic resection                                                    19
                                                                                                                                                                                                                                                                                                                  
  69/M             Incidental on imaging                                                   36 months after treatment for primary lung cancer         2nd part of duodenum                                       Small cell carcinoma      Palliative radiotherapy 30 Gy in 10 fractions                           35
                                                                                                                                                                                                                                                                                                                  
  81/M             Melena, shortness of breath, generalized weakness, symptomatic anemia   1 month after diagnosis of primary lung cancer            4th part of duodenum                                       Squamous cell carcinoma   Palliative radiation and chemotherapy                                   10
                                                                                                                                                                                                                                                                                                                  
  52/M             Epigastric pain, melena, weight loss                                    At time of diagnosis for primary lung cancer              4th part of duodenum                                       Adenocarcinoma            Resection of duodenal mass followed by chemotherapy                     22
                                                                                                                                                                                                                                                                                                                  
  68/M             Iron deficiency anemia                                                  At time of diagnosis for primary lung cancer              Duodenum (unspecified)                                     Adenocarcinoma            Chemotherapy                                                            12
                                                                                                                                                                                                                                                                                                                  
  71/M             Melena, anemia                                                          After one cycle of chemotherapy for primary lung cancer   Duodenum (unspecified)                                     Adenocarcinoma            Chemotherapy                                                            36
                                                                                                                                                                                                                                                                                                                  
  61/F             Worsening epigastric pain, nausea, vomiting, reduced appetite           At time of diagnosis for primary lung cancer              Small bowel (unspecified)                                  Adenocarcinoma            Chemotherapy                                                            37
